A 66-year-old patient from New Hampshire suffering from end-stage kidney disease lived successfully without dialysis for nine months after receiving a genetically modified pig kidney, medical teams announced. Tim Andrews underwent the pioneering procedure in January 2025 at Massachusetts General Hospital, where surgeons used an organ taken from a Yucatan miniature pig engineered for compatibility with the human immune system.
The animal organ served as a temporary bridge while Mr Andrews awaited a transplant from a human donor, remaining functional for 271 days before blood vessel damage led to organ failure and removal. Medical teams documented that the milestone marks the longest recorded dialysis-free survival following a pig kidney transplant in a living patient, opening new paths for addressing global organ shortages.
Surgical Procedure and Genetic Engineering
The kidney transplanted into Mr Andrews was derived from a Yucatan miniature pig and genetically engineered using advanced gene-editing techniques to improve compatibility with human physiology. Medical specialists knocked out specific pig genes to reduce immune recognition and prevent hyperacute rejection, utilizing a single genetic modification to disrupt the gene responsible for alpha-gal production.
Throughout the 271-day duration, monitoring teams reported that no pig viruses or other pathogens were detected at any point during the patient's recovery. Mr Andrews noted that the procedure allowed him to return to normal daily routines, stating in a documentary that he was able to cook, vacuum, and take long walks with his dog Cupcake after years of debilitation.
Clinical Context and Institutional Progress
The milestone follows a series of xenotransplantation studies conducted across specialized institutions in the United States, including prior decedent model studies and living procedures at Massachusetts General Hospital. In 2024, another living pig kidney recipient survived for 52 days before succumbing to unrelated heart issues, while other teams explored combined device and organ interventions.
Lead author Dr. Leonardo Riella, from the center for transplantation sciences at Mass General Brigham, emphasized the scale of the crisis facing modern medicine. "The organ shortage is the greatest crisis we have right now in transplantation," Dr. Riella said, adding that xenotransplantation could eventually bridge the gap for patients awaiting human organs or serve as a destination therapy.
International Perspective and Regulatory Frameworks
While clinical trials and experimental procedures advance rapidly across the United States and China, regulatory bodies in other jurisdictions continue evaluating the safety, ethics, and animal welfare implications of animal-to-human organ procedures. Dr. Rommel Ravanan, chief medical officer for NHS Blood and Transplant in the UK, noted that government-sponsored expert advisory groups have submitted policy recommendations covering oversight and research standards.
Dr. Ravanan emphasized that despite technological breakthroughs involving CRISPR and genetic mapping, significant hurdles remain before xenotransplantation becomes routine clinical practice. Public surveys indicate general support for lifesaving animal-to-human transplants provided rigorous safety and efficacy standards are met.
Future Outlook for Xenotransplantation Research
Researchers and surgical teams anticipate participating in expanded clinical trials under regulatory guidance to further understand the durability of gene-edited animal organs. The success achieved in maintaining organ function for over nine months provides critical data for refining immunosuppression protocols and breeding sustainable organ sources.
Medical authorities continue to stress that while xenotransplantation research progresses, the immediate deficit in organ donations remains acute, urging continued public participation in human organ donor registries to support patients on waiting lists worldwide.
